Marc B. Garnick, MD, presented “How Well Do You Know Doublets and Triplets? – A Pop Quiz” during the 24th Future Directions in Urology Symposium in August 2024 in Colorado Springs, Colorado.
How to cite: Garnick, Marc B. “How Well Do You Know Doublets and Triplets? – A Pop Quiz.” August 2024. Accessed Oct 2024. https://grandroundsinurology.com/how-well-do-you-know-doublets-and-triplets-a-pop-quiz/
How Well Do You Know Doublets and Triplets? – A Pop Quiz – Summary
Marc B. Garnick, MD, tests knowledge on doublet and triplet therapies in prostate cancer. In this quiz-themed 13-minute presentation, he poses a series of questions. After each, he discusses the correct response.
Dr. Garnick begins by matching prostate cancer stages—such as non-metastatic castration-resistant, metastatic castration-sensitive, first-line castration-resistant, and castration-resistant post-docetaxel—with corresponding clinical trials. He incorporates key studies, including SPARTAN, PROSPER, ARAMIS, TITAN, and PREVAIL, and therapies like apalutamide, enzalutamide, daralutamide, and abiraterone in his questions. He also quizzes his audience on side effects and NCCN Guidelines for treating metastatic disease.
The presentation provides a unique comprehensive examination of the landscape of doublet and triplet therapies in prostate cancer, emphasizing the critical importance of personalized treatment approaches based on a detailed understanding of clinical trial data and drug-specific side effect profiles.
The Future Directions in Urology Symposium (FDUS) is an annual urology think tank and non-CME educational summit that brings together industry figures and experts to discuss the current state of genitourinary care and define future directions in treatment. Dr. Dreicer delivered this educational activity during the 24th iteration of the meeting in August 2024 in Colorado Springs, Colorado.
ABOUT THE AUTHOR
Dr. Garnick is the Gorman Brothers Professor of Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center, where he also directs the hospital’s role as a tertiary cancer center for 7 affiliated community cancer centers. He has dedicated his career to the development of new therapies for prostate cancer. He serves as the Editor-in-Chief for The Annual Report on Prostate Diseases, formerly Perspectives on Prostate Disease. He served as the initial academic co-principal investigator for the commonly used prostate cancer drug leuprolide (Lupron). In addition to his academic affiliations, Dr. Garnick founded the Hershey Family Foundation for Prostate Cancer Research at Beth Israel Deaconess Medical Center, serves as medical adviser to World Book Encyclopedia, and is an active advisory member of several FDA panels and advisory committees. He has served on the boards of trustees of the Perelman School of Medicine at the University of Pennsylvania and of Penn Medicine. Dr. Garnick is also a Trustee Emeritus of Bowdoin College in Brunswick, Maine.
